Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Smithgall MC, Yemelyanova A, Mathew S, Gogineni S, He B, Zhang T, et al. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. Int J Gynecol Pathol. 2024;43(2):134-139.

Liu Y-, Geyer JT. Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What We Know and How We Can Apply the Updated Classifications. Pathobiology. 2024;91(1):30-44.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15:363.

Adeuyan O, Magro CM, Trager MH, Gordon ER, Lapolla BA, Schreidah CM, et al. Plasma cell and neutrophil enriched neovascularization with granulomatous lymphangitis in POEMS syndrome. JAAD Case Rep. 2024;49:125-128.

Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, et al. Canonical AREs are tumor suppressive regulatory elements in the prostate. bioRxiv. 2024.

Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, et al. Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. Cancer Res. 2024;84(11):1834-1855.

Yuan G, Lin X, Liu Y, Greenblatt MB, Xu R. Skeletal stem cells in bone development, homeostasis and disease. Protein Cell. 2024.

Keltner NM, Cushing MM, Haas T, Spinella PC. Analyzing and modeling massive transfusion strategies and the role of fibrinogen-How much is the patient actually receiving? Transfusion. 2024.

de Cos M, Mosoyan G, Chauhan K, Troost JP, Wong JS, Lefferts S, et al. Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease. Am J Kidney Dis. 2024.

Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, et al. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024;116(1):115-126.